Fentanyl transdermal patch
Executive Summary
Agreement between Cygnus and Anaquest gives latter exclusive North American marketing rights. Cygnus has been developing the patch for the past 18 months, and Anaquest plans to begin clinical in February 1989. The 24-hour patch product is expected to be used for "post operative pain management and relief for terminally ill patients suffering severe chronic pain." Alza filed an NDA for its fentanyl patch product in December 1987.